SCHEMBL4089699

SCHEMBL4089699

O=C(Nc1ccc(F)cc1)N1CC2C(C1)C2Nc1ncc2cc(-c3ccccc3Cl)c(=O)n(-c3ccc(F)cc3)c2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 6/20 0.47
CNR2 P34972 5/20 0.47
MAPK14 Q16539 5/20 0.43
LCK P06239 1/20 0.43
ABL1 P00519 4/20 0.41
PDGFRB P09619 4/20 0.41
SRC P12931 4/20 0.41
PDGFRA P16234 4/20 0.41
FGFR1 P11362 2/20 0.41
KIT P10721 2/20 0.41
EGFR P00533 1/20 0.41
PAK1 Q13153 1/20 0.39
FGFR2 P21802 2/20 0.39
TNK2 Q07912 3/20 0.39
SIK1 P57059 1/20 0.39
SIK2 Q9H0K1 1/20 0.39
SIK3 Q9Y2K2 1/20 0.39
FGFR4 P22455 1/20 0.38
FGFR3 P22607 1/20 0.38
KDR P35968 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4089107 0.91 MAPK14 (0.46) CNR1CNR2MAPK14LCKABL1
SCHEMBL4095165 0.90 MAPK14 (0.55) MAPK14LCKABL1PDGFRBSRC
SCHEMBL13849301 0.90 MAPK14 (0.47) CNR1CNR2MAPK14LCKABL1
SCHEMBL4091050 0.89 MAPK14 (0.44) CNR1CNR2MAPK14LCKABL1
SCHEMBL4091200 0.89 MAPK14 (0.44) CNR1CNR2MAPK14LCKABL1
SCHEMBL4084691 0.88 MAPK14 (0.44) CNR1CNR2MAPK14LCKABL1
SCHEMBL4091056 0.88 MAPK14 (0.43) CNR1MAPK14LCKABL1PDGFRB
SCHEMBL13849306 0.87 PAK1 (0.42) CNR1CNR2MAPK14LCKABL1
SCHEMBL4088404 0.85 MAPK14 (0.45) CNR1MAPK14LCKABL1PDGFRB
SCHEMBL4089687 0.84 MAPK14 (0.41) CNR1CNR2MAPK14LCKABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 US disclosed
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 US disclosed
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS TLR1, TPMT, NOD1 CNR1 1319/4885CNR2 1798/4885MAPK14 3185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.